Literature DB >> 27557534

Metabolic Reprogramming by the PI3K-Akt-mTOR Pathway in Cancer.

Evan C Lien1, Costas A Lyssiotis2,3, Lewis C Cantley4.   

Abstract

In the past decade, there has been a resurgence of interest in elucidating how metabolism is altered in cancer cells and how such dependencies can be targeted for therapeutic gain. At the core of this research is the concept that metabolic pathways are reprogrammed in cancer cells to divert nutrients toward anabolic processes to facilitate enhanced growth and proliferation. Importantly, physiological cellular signaling mechanisms normally tightly regulate the ability of cells to gain access to and utilize nutrients, posing a fundamental barrier to transformation. This barrier is often overcome by aberrations in cellular signaling that drive tumor pathogenesis by enabling cancer cells to make critical cellular decisions in a cell-autonomous manner. One of the most frequently altered pathways in human cancer is the PI3K-Akt-mTOR signaling pathway. Here, we describe mechanisms by which this signaling network is responsible for controlling cellular metabolism. Through both the post-translational regulation and the induction of transcriptional programs, the PI3K-Akt-mTOR pathway coordinates the uptake and utilization of multiple nutrients, including glucose, glutamine, nucleotides, and lipids, in a manner best suited for supporting the enhanced growth and proliferation of cancer cells. These regulatory mechanisms illustrate how metabolic changes in cancer are closely intertwined with oncogenic signaling pathways that drive tumor initiation and progression.

Entities:  

Keywords:  Akt; Cancer; Metabolism; PI3K; Signaling; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27557534     DOI: 10.1007/978-3-319-42118-6_3

Source DB:  PubMed          Journal:  Recent Results Cancer Res        ISSN: 0080-0015


  60 in total

1.  Fructose-1,6-Bisphosphatase 2 Inhibits Sarcoma Progression by Restraining Mitochondrial Biogenesis.

Authors:  Peiwei Huangyang; Fuming Li; Pearl Lee; Itzhak Nissim; Aalim M Weljie; Anthony Mancuso; Bo Li; Brian Keith; Sam S Yoon; M Celeste Simon
Journal:  Cell Metab       Date:  2019-11-21       Impact factor: 27.287

Review 2.  The PI3K Pathway in Human Disease.

Authors:  David A Fruman; Honyin Chiu; Benjamin D Hopkins; Shubha Bagrodia; Lewis C Cantley; Robert T Abraham
Journal:  Cell       Date:  2017-08-10       Impact factor: 41.582

Review 3.  PI3K signaling in cancer: beyond AKT.

Authors:  Evan C Lien; Christian C Dibble; Alex Toker
Journal:  Curr Opin Cell Biol       Date:  2017-03-24       Impact factor: 8.382

4.  Oncogenic PI3K promotes methionine dependency in breast cancer cells through the cystine-glutamate antiporter xCT.

Authors:  Evan C Lien; Laura Ghisolfi; Renee C Geck; John M Asara; Alex Toker
Journal:  Sci Signal       Date:  2017-12-19       Impact factor: 8.192

Review 5.  Consensus report of the 8 and 9th Weinman Symposia on Gene x Environment Interaction in carcinogenesis: novel opportunities for precision medicine.

Authors:  Michele Carbone; Ivano Amelio; El Bachir Affar; James Brugarolas; Lisa A Cannon-Albright; Lewis C Cantley; Webster K Cavenee; Zhijian Chen; Carlo M Croce; Alan D' Andrea; David Gandara; Carlotta Giorgi; Wei Jia; Qing Lan; Tak Wah Mak; James L Manley; Katsuhiko Mikoshiba; Jose N Onuchic; Harvey I Pass; Paolo Pinton; Carol Prives; Nathaniel Rothman; Said M Sebti; James Turkson; Xifeng Wu; Haining Yang; Herbert Yu; Gerry Melino
Journal:  Cell Death Differ       Date:  2018-10-15       Impact factor: 15.828

Review 6.  Control of B lymphocyte development and functions by the mTOR signaling pathways.

Authors:  Terri N Iwata; Julita A Ramírez-Komo; Heon Park; Brian M Iritani
Journal:  Cytokine Growth Factor Rev       Date:  2017-05-22       Impact factor: 7.638

7.  Oncogenic KRAS signaling activates mTORC1 through COUP-TFII-mediated lactate production.

Authors:  Jun-Kyu Byun; Mihyang Park; Jae Won Yun; Jaebon Lee; Jae Sun Kim; Sung Jin Cho; You Mie Lee; In-Kyu Lee; Yeon-Kyung Choi; Keun-Gyu Park
Journal:  EMBO Rep       Date:  2019-04-15       Impact factor: 8.807

Review 8.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

Review 9.  Antitumor T-cell Reconditioning: Improving Metabolic Fitness for Optimal Cancer Immunotherapy.

Authors:  Dayana B Rivadeneira; Greg M Delgoffe
Journal:  Clin Cancer Res       Date:  2018-01-31       Impact factor: 12.531

10.  Inhibition of protein arginine methyltransferase 5 enhances hepatic mitochondrial biogenesis.

Authors:  Lei Huang; Jehnan Liu; Xiao-Ou Zhang; Katelyn Sibley; Sonia M Najjar; Mary M Lee; Qiong Wu
Journal:  J Biol Chem       Date:  2018-05-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.